Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Inhibitory Effect of Combination with Korean Red Gnseng and Morus Alba in High Fructose-induced Vascular Inflammation and Steatohepatitis

고과당식이 투여 랫드모델에서 홍삼과 상엽 복합투여에 대한 혈관염증 및 지방간염 억제 효과

  • 이윤정 (원광대학교 한의과대학 생리학교실) ;
  • 윤정주 (원광대학교 한의과대학 생리학교실) ;
  • 이소민 (원광대학교 한의과대학 생리학교실) ;
  • 고민철 (원광대학교 한의과대학 생리학교실) ;
  • 김혜윰 (원광대학교 한의과대학 생리학교실) ;
  • 안유미 (원광대학교 한의과대학 생리학교실) ;
  • 고정현 (원광대학교 한의과대학 생리학교실) ;
  • 이기병 (상지대학교 한의과대학) ;
  • 이호섭 (원광대학교 한의과대학 생리학교실) ;
  • 최경민 (진안홍삼연구소) ;
  • 권태오 (원광대학교 생명자원과학대학) ;
  • 강대길 (원광대학교 한의과대학 생리학교실)
  • Received : 2012.08.29
  • Accepted : 2012.10.23
  • Published : 2012.10.25
Download PDF
⟨ Previous Next ⟩

Abstract

This study was designed to elucidate whether combination with Korean red ginseng and Morus alba L. (MPM), traditional treatment for diabetes, ameliorates on high fructose-induced steatohepatitis and vascular inflammation. Animals were divided into four groups; Control receiving tap water, fructose-fed, rosiglitazone-treated fructose-fed rats, and MPM-treated fructose-fed rats both receiving supplemented with 60% fructose (n=10). The MPM or rosiglitazone groups initially received a high-fructose diet alone for 8 weeks, with supplementation with MPM or rosiglitazone, peroxisome proliferators-activated receptor gamma ($PPAR{\gamma}$) agonist, occurring during the final 6 weeks. Treatment with MPM significantly prevented the increase in c-reactive protein (CRP) levels in the high fructose group. MPM suppressed high fructose diet-induced vascular inflammation marker expression such as intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. MPM also reduced intima/media thickness of thoracic aorta. Histologic observation and oil red O staining demonstrated hepatic tissue damage and lipid accumulation were severe in high fructose group. Treatment with MPM ameliorated hepatic tissue morphology with minimized steatosis. In addition, MPM attenuated hepatitis by inhibition of monocyte chemoattractant protein-1 (MCP-1) expression. MPM-fed group showed lower serum GOT and GPT levels comparing with high fructose group. MPM and rosiglitazone (positive control) significantly decreased the size of epididymal adipocytes. Taken together, the administration of MPM inhibited high fructose-induced steatohepatitis and vascular inflammation. These results suggested that MPM is useful in the prevention or treatment of metabolic syndrome-related disorders such as fatty acid metabolism and vascular homeostasis.

Keywords

Acknowledgement

Supported by : 전북농업기술원

References

  1. Georg, P., Ludvik, B. Lipids and diabetes. J. Clin. Basic. Cardiol. 3: 159-162, 2000.
  2. International Diabetes Federation. Diabetes Atlas, 2nd ed, 2003 Available at: www.eatlas.idf.org (accessed on July 12, 2008).
  3. Yoon, K.H., Lee, J.H., Kim, J.W., Cho, J.H., Choi, Y.H., Ko, S.H., Zimmet, P., Son, H.Y. Epidemic obesity and type 2 diabetes in Asia. Lancet. 11: 1681-1688, 2006.
  4. Tay, S.S., Mc Cormack, A., Rose, M.L. Effect of cognate human CD4+ Tcell and endothelial cell interactions upon chemokine production. Transplantatio.n 78(7):987-994, 2004. https://doi.org/10.1097/01.TP.0000137205.26405.40
  5. Uze, G., Pachman, L.M. Cytokines in juvenile dermatomyositis pathophysiology: potential and challenge. Curr. Opin. Rheumatol. 15(6):691-697, 2003. https://doi.org/10.1097/00002281-200311000-00003
  6. Frostegard, J., Wu, R., Haegerstrand, A., patarroyo, M., Lefver,, A.K. Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis. 103: 213-219, 1993. https://doi.org/10.1016/0021-9150(93)90264-U
  7. Mes, Bouhle., M.A., Staels, B., Chinetti-Gbaguid, G. Peroxisome proliferator-activated receptors-from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. J. Intern. Med. 263(1):28-42, 2008.
  8. Li, J.J., Zhu, C.G., Yu, B., Liu, Y.X., Yu, M.Y. The role of inflammation in coronary artery calcification. Agening. Res. Rev. 6(4):263-270, 2007. https://doi.org/10.1016/j.arr.2007.09.001
  9. Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., Mc, Cullough, A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116: 1413-1419, 1999. https://doi.org/10.1016/S0016-5085(99)70506-8
  10. Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Rizzetto, M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123: 134-140, 2002. https://doi.org/10.1053/gast.2002.34168
  11. Marrero, J.A., Fontana, R.J., Su, G.L., Conjeevaram, H.S., Emick, D.M., Lok, A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 36: 1349-1354, 2002. https://doi.org/10.1002/hep.1840360609
  12. Jun, D.W. Non-alcoholic fatty liver disease. Korean J. Hepatol. 17: S332-S336, 2011.
  13. Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., Rizzetto, M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 37: 917-923, 2003. https://doi.org/10.1053/jhep.2003.50161
  14. Hong, M.H., Lim, H.K., Park, J.E., Jun, N.J., Lee, Y.J., Cho, M.J., Kim, S.M. The Antihypertensive and Vasodilating Effects of Adventitious Root Extracts of Wild Ginseng. J. Korean. Soc. Appl. Biol. Chem. 51: 102-107, 2008. https://doi.org/10.3839/jabc.2008.017
  15. Mizuno, M., Yamada, J., Terai, H., Kozukue, N., Lee, Y.S., Tsuchide, H. Differences in immunomodulating effects between wild and cultured Panax ginseng. Biochem. Biophys. Res. Commun. 200: 1672-1678, 1994. https://doi.org/10.1006/bbrc.1994.1644
  16. Kwon, K.R., Park, W.P., Kang, W.M., Jeon, E.Y., Jang, J.H. Identification and analysis of differentially expressed genes in mountain cultivated ginseng and mountain wild ginseng. J. Acupunct. Meridian. Stud. 4: 123-128, 2011. https://doi.org/10.1016/S2005-2901(11)60018-6
  17. Liu, C.X., Xiao, P.G. Recent advances on ginseng research in China. J. Ethnopharmacol. 36: 27-38, 1992. https://doi.org/10.1016/0378-8741(92)90057-X
  18. Kitts, D., Hu, C. Efficacy and safety of ginseng. Public. Health. Nutr. 3: 473-485, 2000.
  19. Enkhmaa, B., Shiwaku, K., Katsube, T., Kitajima, K., Anuurad, E., Yamasaki, M., Yamane, Y. Mulberry (Morus alba L.) leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in LDL receptor-deficient mice. J. Nutr. 135: 729-734, 2005. https://doi.org/10.1093/jn/135.4.729
  20. Miyahara, C., Miyazawa, M., Satoh, S., Sakai, A., Mizusaki, S. Inhibitory effects of mulberry leaf extract on postprandial hyperglycemia in normal rats. J. Nutr. Sci. Vitaminol. 50: 161-164, 2004. https://doi.org/10.3177/jnsv.50.161
  21. Lee, Y.J., Choi, D.H., Kim, E.J., Kim, H.Y., Kwon, T.O., Kang, D.G., Lee, H.S. Hypotensive, hypolipidemic, and vascular protective effects of Morus alba L. in rats fed an atherogenic diet. Am. J. Chin. Med. 39: 39-52, 2011. https://doi.org/10.1142/S0192415X11008634
  22. Park, S.H., Jeon, W.K., Kim, S.H., Kim, H.J., Park, D.I., Cho, Y.K., Sung, I.K., Sohn, C.I., Keum, D.K., Kim, B.I. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 21: 138-143, 2006. https://doi.org/10.1111/j.1440-1746.2005.04086.x
  23. Elliott, S.S., Keim, N.L., Stern, J.S., Teff, K., Havel, P.J. Fructose, weight gain, and the insulin resistance syndrome. Am. J. Clin. Nutr. 76: 911-922, 2002. https://doi.org/10.1093/ajcn/76.5.911
  24. Hwang, I.S., Ho, H., Hoffman, B.B., Reaven, G.M. Fructose-induced insulin resistance and hypertension in rats. Hypertension. 10: 512-516, 1987. https://doi.org/10.1161/01.HYP.10.5.512
  25. Sanchez-Lozada, L.G., Tapia, E., Jimenez, A., Bautista, P., Cristobal, M., Nepomuceno, T., Soto, V., Avila-Casado, C., Nakagawa, T., Johnson, R.J, Herrera-Acosta, J., Franco, M. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am. J. Physiol. Renal. Physiol. 292: 423-429, 2007.
  26. Feingold, K.R., Grunfeld, C. Role of cytokines in inducing hyperlipidemia. Diabetes. 41: 97-101, 1992. https://doi.org/10.2337/diab.41.2.S97
  27. Stenvinkel, P., Heimburger, O., Jogestrand, T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumoniae seropositivity. Am. J. Kidney. Dis. 39: 274-282, 2002. https://doi.org/10.1053/ajkd.2002.30546
  28. Duprez, D.A., Somasundaram, P.E., Sigurdsson, G., Hoke, L., Florea, N., Cohn, J.N. Relationship between Creactive protein and arterial stiffness in an asymptomatic population. J. Hum. Hypertens. 19: 515-519, 2005. https://doi.org/10.1038/sj.jhh.1001860
  29. Hommels, M.J, van der Ven A.J.A.M., Kroon, A.A., Kessels, A.G.H., Van Dieijen-Visser, M.P., Van Engelshoven, J.A.M., Bruggeman, C.A., De Leeuw, P.W. C-reactive protein, atherosclerosis and kidney function in hypertensive patients. J. Hum. Hypertens. 19: 521-526, 2005. https://doi.org/10.1038/sj.jhh.1001878
  30. Quagliaro, L., Piconi, L., Assaloni, R., Da Ros, R., Maier, A., Zuodar, G., Schreyer, S.A., Vick, C., Lystig, T.C., Mystkowski, P., LeBoeuf, R.C. LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am. J. Physiol. Endocrinol. Metab. 282: 207-214, 2002. https://doi.org/10.1152/ajpendo.2002.282.1.E207
  31. Diehl, A.M. Nonalcoholic steatohepatitis. Semin. liver. dis. 19: 220-229, 1999.
  32. Akyuz, F., Demir, K., Ozdil, S., Aksoy, N., Poturoglu, S., Ibrisim, D., Kaymakoglu, S., Besisik, F., Boztas, G., Cakaloglu, Y., Mungan, Z., Cevikbas, U., Okten, A. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig. Dis. Sci. 52:2359-2367, 2007. https://doi.org/10.1007/s10620-006-9145-x
  33. Neuschwander-Tetri, B.A., Brunt, E.M., Wehmeier, K.R., Oliver, D., Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 38: 1008-1017, 2003. https://doi.org/10.1002/hep.1840380427
  34. Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J.Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G.A., Schenker, S., Cusi, K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355: 2297-2307, 2006. https://doi.org/10.1056/NEJMoa060326
  35. Promrat, K., Lutchman, G., Uwaifo, G.I., Freedman, R.J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., Liang, T.J., Yanovski, J.A., Kleiner, D.E., Hoofnagle, J.H. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 39: 188-196, 2004. https://doi.org/10.1002/hep.20012
  36. Fortez, M., Ancellin, N., Andreelli, F., Saintillan, Y., Grondin, P., Kahn, A., Thorens, B., Vaulont, S., Viollet, B. Short-term overexpression of a constitutively active form of AMPK-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes. 54: 1331-1339, 2005. https://doi.org/10.2337/diabetes.54.5.1331
  37. Nielsen, S., Guo, Z., Johnson, C.M., Hensrud, D.D., Jensen, M.D. Splanchnic lipolysis in human obesity. J. Clin. Invest. 113: 1582-1588, 2004. https://doi.org/10.1172/JCI21047
  38. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114: 1752-1761, 2004. https://doi.org/10.1172/JCI21625